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Background. Unoperated severe tricuspid regurgitation (TR) leads to the right ventricle (RV) failure. We wanted to determine if
there was near-term postoperative progression of noncorrected mild to moderate functional TR in patients who underwent mitral
valve surgery for chronic signiﬁcant mitral regurgitation (MR) and if RV size and function were aﬀected. Methods and Results.W e
compared two groups of patients retrospectively. In the ﬁrst group (TVA+, n = 45), tricuspid valve annuloplasty (TVA) had been
performed in conjunction with either mitral valve replacement (MVR) or mitral valve repair (MVP). The second group (TVA−,
n = 22) underwent MVP or MVR without TVA. TVA+ group revealed a signiﬁcant decrease in TR and right ventricle diameter.
In the TVA− group, 7 patients (32%) showed a signiﬁcant progression, by one or more grades, of noncorrected TR together with
dilatation and decreased ejection fraction of the right ventricle. Conclusions. Tricuspid annuloplasty performed concurrently with
MVP or MVR can prevent subsequent progression of tricuspid regurgitation along with right ventricular dilatation and systolic
dysfunction in the near-term postoperative period.
1.Introduction
There are two types of tricuspid regurgitation. Primary
TR, attributed to congenital anomalies or resulting from
bacterial endocarditis, is much less common than secondary
( f u n c t i o n a l )T R[ 1]. Secondary TR is attributed to dilatation
of the right ventricle and tricuspid annulus due to volume or
pressure overloading of the right ventricle.
The most frequent causes of functional TR are [2–5]
(1) left heart disease (signiﬁcant aortic or mitral valve
disorder, or left ventricular dysfunction),
(2) chronic pulmonary disease, and
(3) primary pulmonary hypertension.
Reversible postcapillary or mixed pulmonary hypertension
enabling surgery on an insuﬃcient tricuspid valve usually
accompanies signiﬁcant chronic mitral regurgitation [6].
FunctionalTRmaydecreaseortotallydisappearafterres-
olutionoftheleftheartlesionresponsiblefortheoverloading
of the right ventricle. However, TR progression occurs in as
many as one half of patients [7, 8]. This untreated TR along
with tricuspid annulus dilatation can lead to irreversible
right ventricular dysfunction and failure [3].
When a separate tricuspid valve repair, due to signiﬁcant
TR, follows mitral valve surgery, mortality rates up to 32%
areseen-and5-yearsurvivabilityislessthan50%[9,10].The
reason is the poorer preoperative condition of the patients
due to increased age, complications related to the previous
mitral valve operation, and the possibility that irreversible
right ventricular dysfunction had developed by the time of
the second surgery.
Because of the high total mortality following tricuspid
valve replacement [5], valve repair is preferable [11], and
if tricuspid valve replacement is indicated, a bioprosthetic2 Cardiology Research and Practice
Figure 1: Tricuspid valve annuloplasty using semiﬂexible ring
(provided Doc. Petr Nˇ emec, M.D., PhD., Center of Cardiovascular
and Transplant Surgery, Brno, Czech Republic).
Table 1: Basic characteristics of study groups.
Parameter TVA+ TVA− P
N 45 22
Men/women (n) 18/27 17/5 <.05
Age (years) 71.3 ±6.87 0 ±7.2n s
NYHA 2.9 ±0.62 .6 ±0.8 <.05
LV EF (%) 46.9 ±13.54 1 .1 ±16.0n s
RV EF (%) 46.2 ±7.94 5 .7 ±8.2n s
RV diameter (mm) 28.9 ±4.02 8 .8 ±6.8n s
TR grade 2.0 ±0.81 .7 ±0.7n s
MR grade 3.1 ±0.53 .2 ±0.4n s
TVA+ tricuspid valve annuloplasty, TVA− no tricuspid valve annuloplasty,
NYHA: New York Heart Association classiﬁcation, LV EF: left ventricle
ejection fraction, RV EF: right ventricle ejection fraction, TR: tricuspid
regurgitation, and MR: mitral regurgitation
valve is preferable to a mechanical one. Regarding the
surgery-sparing techniques (for secondary dilatation of the
tricuspid valve annulus with subsequent noncoaptation of
the leaﬂets), placement of sutures around the circumference
oftheannuluswasinitiallyusedtonarrowtheannulus(most
frequently the surgery technique according to De Vega), but
currently not only the narrowing but also the remodeling of
the tricuspid annulus using annuloplasty ring is preferred
(see Figure 1). The advantage of this procedure is a better
long-term outcome of the sparing surgery.
Pulmonary hypertension, higher RV diameter with tri-
cuspid valve annulus dilatation, and decreased RV ejection
fraction are considered risk factors for deterioration of
untreated tricuspid regurgitation following mitral valve
surgery [7, 12]. Therefore tricuspid valve repair in conjunc-
tion with mitral valve surgery is beneﬁcial for severe TR and
should be considered for less than severe TR when there
is dilated annulus (>40mm) or pulmonary hypertension
[7, 11, 13].
The objective of this retrospective analysis was to com-
pare the development of untreated mildly to moderately
signiﬁcant functional TR after an operation for chronic
Table 2: Performed operations.
Parameter TVA+ TVA− P
MVP (n)3 5 1 6n s
MVR (n)1 0 6 n s
CABG (n)2 2 1 5 n s
MAZE (n)1 9 7 n s
TVA+tricuspidannuloplasty,TVA−notricuspidvalveannuloplasty,CABG:
coronary artery bypass graft, MVR: mitral valve replacement, and MVP:
mitral valve repair
Table 3: Comparison of preoperative and 3-month-postoperative
ﬁndings in patients with TVA+.
Parameter Preoperative Postoperative P
NYHA 2.9 ±0.61 .6 ±0.6 <.001
LV EF (%) 46.9 ±13.54 7 .3 ±10.8n s
RV EF (%) 46.2 ±7.94 6 .8 ±7.2n s
RV diameter (mm) 28.9 ±4.02 6 .5 ±3.3 <.05
TR grade 2.0 ±0.77 0.6 ±0.5 <.001
MR grade 3.1 ±0.50 .5 ±0.8 <.001
NYHA: New York Heart Association classiﬁcation, LV EF: left ventricle
ejection fraction, RV EF: right ventricle ejection fraction, TR: tricuspid
regurgitation, and MR: mitral regurgitation.
severe mitral regurgitation in the near-term postoperative
period between a group of patients who had MVR or MVP
o n l ya n dag r o u po fp a t i e n t sw h oh a db o t h( M V Ro rM V P )
and TVA simultaneously.
2. Patients andMethods
We performed a retrospective analysis of 45 patients (TVA+
group) who underwent repair or replacement of the mitral
valve due to signiﬁcant chronic mitral regurgitation of
ischemic or degenerative etiology. Simultaneously, tricuspid
valve annuloplasty was performed with an annuloplastic
ring if the patient had an annulus dilatation greater than
40mm and if at least trace TR was present. This group
of patients was compared with 22 patients (TVA− group)
who underwent only repair or replacement of the mitral
valve. While these patients’ also had an annulus dilated
with more than 40mm and had at least trace TR, TVA
was not performed. Patients with structural tricuspid valve
disorder were not included in the study. There were no
signiﬁcant diﬀerences between the two groups of patients
in terms of age, initial left and right ventricle ejection
fraction, initial tricuspid and mitral regurgitation, and right
ventricle diameter. Estimation of functional stage, using
NYHA classiﬁcation (New York Heart Association), was
done through patients’ questioning. The patients in TVA+
groupwereinasigniﬁcantlyhigherNYHAclassthanpatients
in the TVA− group (Table 1).
2.1. Echocardiography. A transthoracic echocardiographic
examination was performed on both groups of patients
beforetheoperativeprocedureandagain3monthsfollowing
the procedure. The ejection fraction of both ventricles wasCardiology Research and Practice 3
Table 4: Comparison of preoperative and 3-month-postoperative
values in patients with TVA−.
Parameter Preoperative Postoperative P
NYHA 2.5 ±0.81 .5 ±0.5 <.001
LV EF (%) 41.1 ±16 41.3 ±14.9n s
RV EF (%) 45.7 ±8.24 7 .1 ±5.7n s
RV diameter (mm) 28.8 ±6.03 2 .3 ±3.9 <.05
TR grade 1.7 ±0.71 .1 ±1.2 <.05
MR grade 3.2 ±0.40 .2 ±0.4 <.001
NYHA: New York Heart Association classiﬁcation, LV EF: left ventricle
ejection fraction, RV EF: right ventricle ejection fraction, TR: tricuspid
regurgitation, and MR: mitral regurgitation.
assessed; the right ventricle diameter in long-axis paraster-
nal view (PLAX) was measured. TR grade was assessed
semiquantitatively according to Color Doppler Flow (CFM)
from the apical four-chamber view (0,5 degree: trace, First
degree: to 1/3 of the right atrium (RA), Second degree:
1/3–1/2 of RA, Third degree: 1/2–2/3 of RA, Forth degree:
2/3–the full length of RA). Mitral regurgitation was also
assessed semiquantitatively using CFM from the apical four-
chamber view. The estimation of systolic pressure in the
pulmonary artery, based on the peak regurgitation gradient
of the tricuspid valve, was not performed for all patients.
Therefore, this value was not included in the retrospective
analysis.
2.2. Surgical Technique. All patients were operated on via
median sternotomy. Crystalloid antegrade cardioplegia was
used as myocardial protection. In the TVA+ group, mitral
valve repair was performed on 35 patients (78%) and
mitral valve replacement on 10 patients (22%), while 22
patients (49%) also underwent aortocoronary bypass graft
(CABG). Additionally, 19 patients (42%) underwent the
MAZE procedure. In the TVA− group, mitral valve repair
was performed on 16 patients (73%), valve replacement
on 6 patients (27%), while 15 patients (68%) underwent
CABG. Additionally, 7 patients (32%) underwent the MAZE
procedure. In both groups, CABG was performed either as
a primary indication or as a supplementary operation. The
survey is shown in Table 2.
2.3. Statistical Methods. The Student’s t-test and Mann-
Whitney U test were used for statistical evaluation.
3. Results
There was a trend for a higher one-month and three-
month mortality in TVA− group (Figure 2). The NYHA
class improved for both groups. The TVA+ group showed
a statistically signiﬁcant decrease in right ventricle diameter
but a nonsigniﬁcant increase in right and left ventricle
ejection fractions. The decrease in the average grade of TR
was statistically signiﬁcant (Table 3). None of the patients in
theTVA+groupexperiencedprogressioninTRbymorethan
one grade.
Table 5: Comparison of preoperative and 3-month-postoperative
ﬁndings in patients with TVA− a n dw i t hT Rp r o g r e s s i o nb yo n eo r
more grades.
Parameter Preoperative Postoperative P
NYHA 2.4 ±0.61 .6 ±0.5 <.05
LV EF (%) 47.5 ±16.34 6 .8 ±17.6n s
RV EF (%) 50.0 ±04 3 .3 ±7.7 <.05
RV diameter (mm) 27.4 ±3.43 4 ±3.9 <.01
TR grade 1.1 ±0.82 .6 ±0.5 <.001
MR grade 3.2 ±0.50 .5 ±0.4 <.001
NYHA: New York Heart Association classiﬁcation, LV EF: left ventricle
ejection fraction, RV EF: right ventricle ejection fraction, TR: tricuspid
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Figure 2: One month and three months mortality in TVA+ and
TVA− groups.
Like the TVA+ group, the TVA− group showed a
statistically signiﬁcant NYHA class improvement as well as
a TR-grade decrease and a non-signiﬁcant increase in the
ejection fraction of both ventricles. However, the TVA−
group showed a statistically signiﬁcant dilatation of the right
ventricle (Table 4). Seven patients (32%), from the TVA−
group had postoperative TR progression by more than one
grade with clinically signiﬁcant right ventricular dilatation
and decreases in ejection fraction (Table 5). There were no
diﬀerences in the baseline characteristics (age, NYHA class,
echocardiographic parameters) between these seven patients
and the rest of the TVA- group.
4. Discussion
The signiﬁcance of TR has been often overlooked in cardio-
surgery [8], however the importance of this issue has been
recently addressed in the updated guidelines of both the
ACC/AHA and ESC valve disease [11, 13].
Most patients in the TVA+ group showed a signiﬁcant
decrease in TR grade, and there were no instances of
annuloplasty failure reported. The reason that 1/3 of the
patients showed no signiﬁcant decrease in TR after TVA is
duetothefactthatinthesepatientsonlytraceTRwaspresent4 Cardiology Research and Practice
at the time of the operation, and trace TR remained even
after the operation. A signiﬁcant improvement in dyspnea
was obvious in both groups, and it can be attributed to the
resolution of the left heart lesion or, in selected cases, lesion
resolution plus revascularization. Left ventricular function
was not signiﬁcantly aﬀected by the mitral valve operation
in either group.
The TVA− group also showed a statistically signiﬁcant
decreasein TR. Wecan only speculatethatthe most probable
cause was the that resolution of the left heart lesion brought
about a subsequent reduction in pulmonary hypertension,
however pulmonary hypertension was not systematically
measured in our study. If this speculation is correct, then
it would, at least in the near-term postoperative period,
oppose the statement that pulmonary hypertension is not a
signiﬁcant determinant of functional TR [8, 14, 15]. About
1/3 of the patients in the TVA− group showed TR progres-
sion by more than one grade and entered the classiﬁcation
of moderate to severe TR combined with dilatation and
decreasedrightventriclefunction.Thepercentageofpatients
experiencing a progression in TR is in agreement with the
data presented in the literature [7, 8]. Nevertheless, the
follow-up periods in these studies were markedly longer,
ranging from one to ten years [7, 8, 15]. In the study by
Metsunaga and Duran [8], the number of patients with
functional TR after mitral valve repair gradually increased
with time, and so we cannot exclude that in a longer
follow-up; the percentage of patients who experienced a
progression of TR would also be higher in our study. A
signiﬁcant progression in TR appeared only in some of
the patients in the TVA− group. However, none of the
patients in the TVA+ group experienced progression in TR
by more than one grade, which supports the hypothesis
that noncorrected preoperative tricuspid annulus dilatation
can lead to postoperative TR progression [7]. Another
reason for TR progression can be a temporary increase in
pulmonary vascular resistance following surgery, which is
related to extracorporeal circulation [16], as well as the
possible inﬂuence of temporary postoperative hypervolemia.
5. Study limitations
Our study has several limitations. First, it was retrospective
in nature and non-randomized. Second, echocardiographic
evaluation was performed only using transthoracic exami-
nation, and the evaluation of valve regurgitation was only
semi-quantitative, which is in accordance with current
clinical practice. Finally, the presence as well as the grade
of pulmonary hypertension was not routinely echocardio-
graphically assessed in all patients, so these data could not
be used in our analysis.
6. Conclusion
The results of our retrospective analysis support the latest
guidelines for treatment of TR associated with mitral valve
disease [11, 13]. These guidelines suggest, and our study
substantiates, that concurrent tricuspid valve surgery should
be considered for less than severe TR when there is dilated
annulus >40mm or pulmonary hypertension.
We conclude that tricuspid valve annuloplasty of the
tricuspid annulus dilated >40mm, together with trace to
moderate tricuspid regurgitation, performed concurrently
with a mitral valve operation can prevent subsequent
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